This information does not constitute an offer, or an invitation to purchase, securities of Abu Dhabi Developmental Holding Company PJSC (ADQ) in the United States or in any other jurisdiction in which such offer or invitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation.  Potential users of this information are requested to inform themselves about and to observe any such restrictions.ADQ's securities cannot be offered, sold, transferred or otherwise disposed of, in the United States, or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act of 1933, as amended (the Securities Act)), absent registration, or an exemption from, or in a transaction not subject to, the registration requirements under the Securities Act.  ADQ has not registered, and does not intend to register, any of its securities under the Securities Act or to conduct a public offering of securities in the United States.This communication has not been approved by the United Kingdom Financial Conduct Authority. This communication does not constitute an offer of the securities to the public in the United Kingdom. This communication is being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Order), and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order, and (iv) any other persons to whom it may otherwise lawfully be communicated or caused to be communicated (all such persons in (i) to (iv) together being referred to as Relevant Persons). Any investment activity to which this communication relates will only be available to and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this communication or any of its contents.This is an advertisement and not a prospectus for the purposes of Regulation (EU) 2017/1129 (the Prospectus Regulation). Investors should not subscribe for or purchase any securities referred to in this advertisement except on the basis of information contained in the base prospectus.

ADQ paper sets out opportunities to redefine regional pharma and enhance local competitiveness in the UAE


  • New ADQ FWD paper identifies the cornerstones of success to enhance regional pharmaceutical capacity to advance affordable, quality medication and innovative treatments
  • Drivers include growing the talent pool, biotech and life sciences parks, increasing manufacturing capabilities, building a pharma R&D ecosystem and incentives

ADQ, an Abu Dhabi-based investment and holding company, today launched its ADQ FWD paper that explores the opportunities and investments that will position the UAE to become a leading regional pharma manufacturing hub.

The paper, Redefining Regional Pharma, focuses on how the nation can reach its full potential to increase regional pharmaceutical capacity and create seamless access to affordable medications and innovative treatments.

The paper identifies six cornerstones of success to enable the UAE to capture pharma growth opportunities in the region:

  1. Drive collaboration among stakeholders: Byestablishing cooperation between the public and private sectors and academia, public health programs and research can be more robust
  2. Establish a robust life sciences R&D ecosystem: The UAE’s knowledge-based economy will be instrumental for accelerating R&D and the production of novel and innovative medicines and vaccines
  3. Develop UAE-based biotech and life sciences parks: Building a purpose-built R&D hub for life sciences, biotechnology and vaccine production
  4. Increase the UAE’s manufacturing capabilities: Progressing the Basic Industries Project with investment into industrial areas that promote self-sufficient production of basic and consumer commodities
  5. Capture the use of cutting-edge technologies: Bilateral relationships need to be further leveraged to foster investment in clinical research that addresses healthcare needs
  6. Grow a highly skilled talent pool: Nurturing diverse skillsets in various healthcare disciplines to develop homegrown talent and expertise

We are deploying capital to build a pharma hub that further strengthens the UAE’s regional leadership in the industry. As we invest in expanding capabilities, deepening the talent pool and increasing manufacturing drugs locally, we are helping to redefine the regional pharma landscape. This paper emphasizes the importance we place on ensuring that our community has access to essential pharmaceuticals for the long-term, which is one of the key aspects of our commitment to being a sustainable investor.

Fahad Al Qassim, Executive Director, Healthcare & Life Sciences, ADQ

ADQ FWD is a platform that brings together industry experts, government, and advocacy leaders to discuss matters of economic and strategic importance.

About ADQ

Established in 2018, ADQ is an Abu Dhabi-based investment and holding company with a broad portfolio of major enterprises. Its investments span key sectors of the UAE’s diversified economy including energy and utilities, food and agriculture, healthcare and life sciences, and mobility and logistics, amongst others. As a strategic partner of Abu Dhabi’s government, ADQ is committed to accelerating the transformation of the Emirate into a globally competitive and knowledge-based economy.

For more information, visit adq.ae or write to media@adq.ae. You can also follow ADQ on X, Instagram and LinkedIn.

Direct to your inbox

ADQ News and Insights delivered directly to your inbox

Latest News

The ADQ FWD platform brings together industry experts, government, and advocacy leaders to discuss and address issues of economic and strategic importance for the UAE.